| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1173: Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor |
|
Medicine details |
|
| Medicine name | Pirtobrutinib (Jaypirca®) |
| Formulation | 100 mg film-coated tablets |
| Reference number | 5316 |
| Indication | Treatment for relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Advice number | ID6269 |
| Date of issue | 05/06/2026 |
| NICE guidance | |